GB201701194D0 - Antigen binding molecules that bind light - Google Patents

Antigen binding molecules that bind light

Info

Publication number
GB201701194D0
GB201701194D0 GBGB1701194.1A GB201701194A GB201701194D0 GB 201701194 D0 GB201701194 D0 GB 201701194D0 GB 201701194 A GB201701194 A GB 201701194A GB 201701194 D0 GB201701194 D0 GB 201701194D0
Authority
GB
United Kingdom
Prior art keywords
antigen binding
binding molecules
bind light
bind
light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1701194.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capella Bioscience Ltd
Original Assignee
Capella Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capella Bioscience Ltd filed Critical Capella Bioscience Ltd
Priority to GBGB1701194.1A priority Critical patent/GB201701194D0/en
Publication of GB201701194D0 publication Critical patent/GB201701194D0/en
Priority to KR1020197024448A priority patent/KR20190110578A/ko
Priority to GB1820446.1A priority patent/GB2566389B/en
Priority to CN201880019587.7A priority patent/CN110461875B/zh
Priority to US16/480,367 priority patent/US11827673B2/en
Priority to PCT/GB2018/050203 priority patent/WO2018138496A1/en
Priority to JP2019560493A priority patent/JP7140403B2/ja
Priority to EP18702792.5A priority patent/EP3574014A1/en
Priority to US18/480,379 priority patent/US20240294655A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
GBGB1701194.1A 2017-01-24 2017-01-24 Antigen binding molecules that bind light Ceased GB201701194D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1701194.1A GB201701194D0 (en) 2017-01-24 2017-01-24 Antigen binding molecules that bind light
KR1020197024448A KR20190110578A (ko) 2017-01-24 2018-01-24 Light에 결합하는 항원 결합 분자
GB1820446.1A GB2566389B (en) 2017-01-24 2018-01-24 Antigen binding molecules that bind light
CN201880019587.7A CN110461875B (zh) 2017-01-24 2018-01-24 结合light的抗原结合分子
US16/480,367 US11827673B2 (en) 2017-01-24 2018-01-24 Antigen binding molecules that bind light
PCT/GB2018/050203 WO2018138496A1 (en) 2017-01-24 2018-01-24 Antigen binding molecules that bind light
JP2019560493A JP7140403B2 (ja) 2017-01-24 2018-01-24 Ｌｉｇｈｔに結合する抗原結合分子
EP18702792.5A EP3574014A1 (en) 2017-01-24 2018-01-24 Antigen binding molecules that bind light
US18/480,379 US20240294655A1 (en) 2017-01-24 2023-10-03 Antigen binding molecules that bind light

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1701194.1A GB201701194D0 (en) 2017-01-24 2017-01-24 Antigen binding molecules that bind light

Publications (1)

Publication Number Publication Date
GB201701194D0 true GB201701194D0 (en) 2017-03-08

Family

ID=58463068

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1701194.1A Ceased GB201701194D0 (en) 2017-01-24 2017-01-24 Antigen binding molecules that bind light
GB1820446.1A Active GB2566389B (en) 2017-01-24 2018-01-24 Antigen binding molecules that bind light

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1820446.1A Active GB2566389B (en) 2017-01-24 2018-01-24 Antigen binding molecules that bind light

Country Status (7)

Country Link
US (2) US11827673B2 (enExample)
EP (1) EP3574014A1 (enExample)
JP (1) JP7140403B2 (enExample)
KR (1) KR20190110578A (enExample)
CN (1) CN110461875B (enExample)
GB (2) GB201701194D0 (enExample)
WO (1) WO2018138496A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114516913B (zh) * 2020-11-19 2023-04-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体和检测试剂盒
KR20250151071A (ko) 2024-04-13 2025-10-21 백수경 이동식 방제 박스

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3734795A (en) 1971-04-23 1973-05-22 Lindsay Wire Weaving Co Patch and seam for plastic belts
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
AU8755798A (en) 1997-04-04 1998-11-13 Biosite Diagnostics Incorporated Polyvalent and polyclonal libraries
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US6140467A (en) 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
DK1674575T3 (da) 2000-04-12 2010-11-29 Jolla Inst Allergy Immunolog Ligand for Herpes simplex-indgangsmediator og fremgangsmåder til anvendelse
EP1336619A3 (en) 2002-02-19 2003-12-10 Millenium Pharmaceuticals, Inc. Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
CA2481401A1 (en) 2002-04-15 2003-10-30 Human Genome Sciences, Inc. Antibodies that specifically bind to tl5
EP2484696B1 (en) * 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
UA99714C2 (ru) * 2006-08-28 2012-09-25 Ля Хойя Інстітьют Фор Еллерджи Енд Іммьюнолоджи Моноклональное антитело, которое специфически связывается с light
US8440185B2 (en) 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
WO2008145142A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
EP2207597B1 (en) 2007-09-18 2020-02-19 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
JP2012521216A (ja) 2009-03-24 2012-09-13 テバ バイオファーマスーティカルズ ユーエスエー，インコーポレーテッド Ｌｉｇｈｔに対するヒト化抗体およびその使用
WO2013148350A2 (en) * 2012-03-26 2013-10-03 Sanofi Anti-light antibody therapy for inflammatory bowel disease
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CA3204402A1 (en) 2012-03-26 2013-10-03 Sanofi Stable anti-cxcr5 igg4 antibody formulations
CA2922375C (en) 2013-09-06 2021-06-15 Research Development Foundation Alpha-tea salt forms: compositions and uses for treating disease
JP6508785B2 (ja) 2013-10-25 2019-05-08 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
JP2017504327A (ja) * 2014-01-14 2017-02-09 カイマブ・リミテッド 抗ｌｉｇｈｔ抗体
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
WO2016127059A2 (en) 2015-02-05 2016-08-11 La Jolla Institute For Allergy And Immunology Light inhibitors for scleroderma and skin fibrotic disease treatment
EP3337509A4 (en) 2015-08-21 2019-01-02 The Children's Hospital of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
US11312781B2 (en) * 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT

Also Published As

Publication number Publication date
GB2566389B (en) 2019-08-21
GB2566389A (en) 2019-03-13
JP7140403B2 (ja) 2022-09-21
CN110461875A (zh) 2019-11-15
US11827673B2 (en) 2023-11-28
WO2018138496A1 (en) 2018-08-02
US20240294655A1 (en) 2024-09-05
JP2020505465A (ja) 2020-02-20
CN110461875B (zh) 2023-07-21
US20210284747A1 (en) 2021-09-16
EP3574014A1 (en) 2019-12-04
GB201820446D0 (en) 2019-01-30
KR20190110578A (ko) 2019-09-30

Similar Documents

Publication Publication Date Title
IL275510A (en) Specific antigen-binding molecules-ROR1
ZA202203250B (en) Cd3 binding antibodies
IL260846B (en) Antigen binding proteins that bind pd-l1
IL277848A (en) HER2-targeting antigen-binding molecules containing 4-1BBL
IL263840A (en) cd3 binding antibodies
IL256848A (en) Antibody molecules that bind cd45
DK3645571T3 (da) Her3-antigen-bindende molekyler
IL256846A (en) antibody molecules that bind cd22
ZA201701912B (en) Antigen binding proteins that bind cxcr5
GB201612520D0 (en) Binding molecules
IL256853A (en) antibody molecules that bind cd79
GB201811403D0 (en) Antibody molecules
GB201811410D0 (en) OX40 Binding molecules
SG11202004904XA (en) Binding molecules that specifically bind to tau
GB201702091D0 (en) Specific binding molecules
EP3131574A4 (en) Antigen binding proteins that bind wisp1
IL274676A (en) The bispecific antigen binding composition
ZA201701941B (en) Antigen binding proteins that bind cxcr3
IL269752B (en) fgfr3 binding molecules
ZA201906821B (en) Anti-jagged1 antigen binding proteins
GB201820446D0 (en) Antigen binding molecules that bind light
EP3458484A4 (en) ANTIBODY BINDING NANOFIBRILLES
GB201614627D0 (en) Antigen binding proteins
HK40017324A (en) Antigen binding molecules that bind light
HK40037670A (en) Ror1-specific antigen binding molecules

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)